Publication Details
Abstract
For nearly half a century, cisplatin has stood as both a beacon of hope and a testament to the enduring struggle against cancer. Discovered serendipitously in the 1960s and granted FDA approval in 1978, this small platinum molecule transformed testicular cancer from a death sentence into a largely curable disease—saving countless young lives and reshaping the landscape of oncology. Yet behind this triumph lies a profound paradox: the very compound that brings healing also inflicts suffering. In response, science has not stood still. Next-generation analogs—carboplatin, oxaliplatin, nedaplatin, lobaplatin—have emerged with gentler toxic profiles, each carrying the legacy of their predecessor while seeking to soften its blows. Nanotechnology wraps the drug in protective carriers, guiding it toward tumors like a letter with a specific address. Combination therapies pair platinum with molecular partners—PI3K inhibitors, PARP inhibitors, immune checkpoint blockers—creating synergies that outsmart resistance. Epigenetic modulators and natural compounds, from curcumin to resveratrol, offer gentler hands to sensitize resistant cells. This review journeys through the molecular soul of cisplatin—from its chemical awakening in aqueous solutions, through its cellular travels and nuclear battles, to the clinical theaters where it saves and harms. We examine the mechanisms that make it work, the resistances that make it fail, and the innovations that seek to honor its legacy while transcending its limitations. For in the end, cisplatin is more than a drug; it is a chapter in humanity's ongoing dialogue with disease—a reminder that even our most powerful medicines carry the weight of compromise, and that the future of cancer care lies not in abandoning such tools, but in refining them with wisdom, precision, and ever-deepening compassion.